New antibody drug firsekibart tested for scleroderma skin thickening

NCT ID NCT07502105

Not yet recruiting Disease control Sponsor: Tongji Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test a new drug called firsekibart in 30 people with systemic sclerosis (scleroderma), a disease that causes skin thickening and organ damage. Firsekibart is an antibody that blocks a protein involved in inflammation. The study will measure changes in skin thickness over time and compare results to past patient data to see if the drug is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: firsekibart (a lab-made antibody that blocks IL-1β, a protein involved in inflammation)
What this could lead to: If it works, this could point toward a new treatment option for systemic sclerosis, potentially reducing skin thickening and improving quality of life.
What could go wrong: This is a very early, small, exploratory trial with only 30 participants and no placebo group. Results may not be generalizable, and the drug's safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse cutaneous systemic sclerosis systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC SCLERODERMA

Contacts and locations

Locations

Tongji Hospital, Tong ji Medical Colledge

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.